Found: 42
Select item for more details and to access through your institution.
Colesevelam for lenalidomide associated diarrhea in patients with multiple myeloma.
- Published in:
- Blood Cancer Journal, 2024, v. 14, n. 1, p. 1, doi. 10.1038/s41408-024-01136-1
- By:
- Publication type:
- Article
Prognostic impact of corticosteroid and tocilizumab use following chimeric antigen receptor T-cell therapy for multiple myeloma.
- Published in:
- Blood Cancer Journal, 2024, v. 14, n. 1, p. 1, doi. 10.1038/s41408-024-01048-0
- By:
- Publication type:
- Article
Comparison of infectious complications with BCMA-directed therapies in multiple myeloma.
- Published in:
- Blood Cancer Journal, 2024, v. 14, n. 1, p. 1, doi. 10.1038/s41408-024-01043-5
- By:
- Publication type:
- Article
Bortezomib, lenalidomide and dexamethasone (VRd) vs carfilzomib, lenalidomide and dexamethasone (KRd) as induction therapy in newly diagnosed multiple myeloma.
- Published in:
- Blood Cancer Journal, 2023, v. 13, n. 1, p. 1, doi. 10.1038/s41408-023-00882-y
- By:
- Publication type:
- Article
Hematology .
- Published in:
- 2000
- By:
- Publication type:
- Book Review
Hematology.
- Published in:
- 1999
- By:
- Publication type:
- Book Review
A Case of Protothecosis in a Patient with Multiple Myeloma.
- Published in:
- Journal of Cutaneous Pathology, 2014, v. 41, n. 5, p. 409, doi. 10.1111/cup.12338
- By:
- Publication type:
- Article
Comparison of venous thromboembolism incidence in newly diagnosed multiple myeloma patients receiving bortezomib, lenalidomide, dexamethasone (RVD) or carfilzomib, lenalidomide, dexamethasone (KRD) with aspirin or rivaroxaban thromboprophylaxis.
- Published in:
- British Journal of Haematology, 2022, v. 196, n. 1, p. 105, doi. 10.1111/bjh.17772
- By:
- Publication type:
- Article
Comparison of MALDI‐TOF mass spectrometry analysis of peripheral blood and bone marrow‐based flow cytometry for tracking measurable residual disease in patients with multiple myeloma.
- Published in:
- British Journal of Haematology, 2020, v. 189, n. 5, p. 904, doi. 10.1111/bjh.16443
- By:
- Publication type:
- Article
Clinical efficacy of sequencing CD38 targeting monoclonal antibodies in relapsed refractory multiple myeloma: A multi‐institutional experience.
- Published in:
- American Journal of Hematology, 2022, v. 97, n. 7, p. E276, doi. 10.1002/ajh.26580
- By:
- Publication type:
- Article
A phase I/II study of ixazomib, pomalidomide, and dexamethasone for lenalidomide and proteasome inhibitor refractory multiple myeloma (Alliance A061202).
- Published in:
- American Journal of Hematology, 2021, v. 96, n. 12, p. 1595, doi. 10.1002/ajh.26361
- By:
- Publication type:
- Article
Tailored treatment to MRD response: A phase I/II study for newly diagnosed multiple myeloma patients using high dose twice‐weekly carfilzomib (45 and 56 mg/m<sup>2</sup>) in combination with lenalidomide and dexamethasone.
- Published in:
- American Journal of Hematology, 2021, v. 96, n. 6, p. E193, doi. 10.1002/ajh.26150
- By:
- Publication type:
- Article
Challenging diagnosis of intra-diverticular colonic adenocarcinoma with submucosal localization.
- Published in:
- 2013
- By:
- Publication type:
- Case Study
Clonal plasma cell pathophysiology and clinical features of disease are linked to clonal plasma cell expression of cyclin D1 in systemic light-chain amyloidosis.
- Published in:
- 2012
- By:
- Publication type:
- journal article
Spinal cord compression secondary to extramedullary hematopoiesis: A noninvasive management based on MRI.
- Published in:
- American Journal of Hematology, 1991, v. 37, n. 3, p. 201, doi. 10.1002/ajh.2830370314
- By:
- Publication type:
- Article
Multiple myeloma with simultaneous cutaneous and central nervous system involvement.
- Published in:
- Clinical Case Reports, 2018, v. 6, n. 10, p. 2015, doi. 10.1002/ccr3.1626
- By:
- Publication type:
- Article
P-216: Daratumumab, Carfilzomib, Lenalidomide, & Dexamethasone for relapsed/refractory Myeloma with salvage autologous hematopoietic cell transplant: interim analysis of the multicenter 2nd chance protocol.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S158, doi. 10.1016/S2152-2650(21)02343-0
- By:
- Publication type:
- Article
P-152: Providing nutritional guidance for patients with plasma cell disorders – a missed opportunity for hematologists and oncologists?
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S118, doi. 10.1016/S2152-2650(21)02279-5
- By:
- Publication type:
- Article
P-042: Sustained minimal residual disease negativity in Multiple Myeloma is impacted positively by stool butyrate and healthier plant forward diets.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S61, doi. 10.1016/S2152-2650(21)02176-5
- By:
- Publication type:
- Article
MM-186: HORIZON (OP-106): Melflufen Plus Dexamethasone in 55 Patients with Relapsed/Refractory Multiple Myeloma (RRMM) with Extramedullary Disease (EMD): Subgroup Analysis.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S427, doi. 10.1016/S2152-2650(21)01953-4
- By:
- Publication type:
- Article
MM-171: Melflufen Plus Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Exposed or Refractory to Prior Alkylators: A Pooled Analysis of the O-12-M1 and HORIZON Studies.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S426, doi. 10.1016/S2152-2650(21)01952-2
- By:
- Publication type:
- Article
Poster: MM-186: HORIZON (OP-106): Melflufen Plus Dexamethasone in 55 Patients with Relapsed/Refractory Multiple Myeloma (RRMM) with Extramedullary Disease (EMD): Subgroup Analysis.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S250, doi. 10.1016/S2152-2650(21)01573-1
- By:
- Publication type:
- Article
Poster: MM-171: Melflufen Plus Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Exposed or Refractory to Prior Alkylators: A Pooled Analysis of the O-12-M1 and HORIZON Studies.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S251, doi. 10.1016/S2152-2650(21)01575-5
- By:
- Publication type:
- Article
Vitiligo Following Autologous Hematopoietic Stem Cell Transplantation.
- Published in:
- 2020
- By:
- Publication type:
- Case Study
Phase I Study of Selinexor, Ixazomib, and Low-dose Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma.
- Published in:
- 2020
- By:
- Publication type:
- clinical trial
Activity of Melflufen in RR MM Patients with Extramedullary Disease in the Phase 2 HORIZON Study (OP-106): Promising Results in a High-Risk Population.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. e352, doi. 10.1016/j.clml.2019.09.582
- By:
- Publication type:
- Article
A phase 1/2 study to assess safety and dose of ixazomib in combination with cyclophosphamide and dexamethasone in newly diagnosed patients with light chain (AL) amyloidosis.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. e330, doi. 10.1016/j.clml.2019.09.543
- By:
- Publication type:
- Article
Depth of Response and Outcomes by Initial Therapy Prior to Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. e298, doi. 10.1016/j.clml.2019.09.490
- By:
- Publication type:
- Article
BCMA expression in AL Amyloidosis.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. e306, doi. 10.1016/j.clml.2019.09.503
- By:
- Publication type:
- Article
Practice Patterns with Focal Progression on Daratumumab Therapy.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. e142, doi. 10.1016/j.clml.2019.09.237
- By:
- Publication type:
- Article
Stem Cell Mobilization and Autograft Purity with Novel Induction Regimens in Multiple Myeloma.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. e46, doi. 10.1016/j.clml.2019.09.070
- By:
- Publication type:
- Article
HORIZON (OP-106) Study of Melflufen in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Refractory to Daratumumab and/or Pomalidomide: Updated Efficacy and Safety.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. S329, doi. 10.1016/j.clml.2019.07.318
- By:
- Publication type:
- Article
Galinpepimut-S, a WT1-Targeting Immuno-Oncology Treatment, Induces Specific, Robust and Durable Immune Responses (IRs) in Patients (Pts) with High-Risk (HR) Multiple Myeloma (MM).
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2017, v. 17, p. S343, doi. 10.1016/j.clml.2017.07.164
- By:
- Publication type:
- Article
Re-immunization following Autologous Hematopoietic Stem Cell Transplantation (Auto HCT) is Safe and Effective in Patients with Multiple Myeloma Receiving Lenalidomide Maintenance.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2017, v. 17, p. e82, doi. 10.1016/j.clml.2017.03.149
- By:
- Publication type:
- Article
Improvement of Response for Multiple Myeloma patients on Lenalidomide Maintenance after Autologous Hematopoietic Stem Cell Transplantation (Auto HCT).
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2017, v. 17, p. e140, doi. 10.1016/j.clml.2017.03.253
- By:
- Publication type:
- Article
Outcomes of renal transplantation in patients with AL amyloidosis: an international collaboration through The International Kidney and Monoclonal Gammopathy Research Group.
- Published in:
- Blood Cancer Journal, 2022, v. 12, n. 8, p. 1, doi. 10.1038/s41408-022-00714-5
- By:
- Publication type:
- Article
Nutrition perceptions, needs and practices among patients with plasma cell disorders.
- Published in:
- 2022
- By:
- Publication type:
- Letter
Monoclonal gammopathy‐associated thrombotic microangiopathy.
- Published in:
- American Journal of Hematology, 2019, v. 94, n. 10, p. E250, doi. 10.1002/ajh.25569
- By:
- Publication type:
- Article
Allopurinol-induced pure red cell aplasia.
- Published in:
- American Journal of Hematology, 2003, v. 73, n. 1, p. 69, doi. 10.1002/ajh.10315
- By:
- Publication type:
- Article
Risk-adapted autologous stem cell transplantation with adjuvant dexamethasone ± thalidomide for systemic light-chain amyloidosis: results of a phase II trial.
- Published in:
- British Journal of Haematology, 2007, v. 139, n. 2, p. 224, doi. 10.1111/j.1365-2141.2007.06783.x
- By:
- Publication type:
- Article
Doxorubicin and dexamethasone followed by thalidomide and dexamethasone is an effective well tolerated initial therapy for multiple myeloma.
- Published in:
- British Journal of Haematology, 2006, v. 132, n. 2, p. 155, doi. 10.1111/j.1365-2141.2005.05848.x
- By:
- Publication type:
- Article
Beta-Spectrin S[supta] Barbara: a novel frameshift mutation in hereditary spherocytosis associated with detectable levels of mRNA and a germ cell line mosaicism.
- Published in:
- British Journal of Haematology, 2001, v. 115, n. 2, p. 347, doi. 10.1046/j.1365-2141.2001.03103.x
- By:
- Publication type:
- Article